Screener
Axsome Therapeutics AXSM Goodwill
Goodwill at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total current assets | 611,206 | 588,986 |
| Equipment, net | 567 | 562 |
| Right-of-use asset - operating lease | 20,014 | 20,858 |
| Goodwill | 12,042 | 12,042 |
| Intangible asset, net | 38,947 | 40,519 |
| Non-current inventory and other assets | 30,831 | 26,838 |
| Total assets | $713,607 | $689,805 |
| Liabilities and stockholders’ equity |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's goodwill?
- Axsome Therapeutics (AXSM) reported goodwill of $12.04M in Q1 2026.
- How has Axsome Therapeutics's goodwill changed year-over-year?
- Axsome Therapeutics's goodwill decreased by 0.0% year-over-year, from $12.04M to $12.04M.
- What is the long-term trend for Axsome Therapeutics's goodwill?
- Over 3 years (2022 to 2025), Axsome Therapeutics's goodwill has grown at a 5.3% compound annual growth rate (CAGR), from $10.31M to $12.04M.
- What does goodwill mean?
- The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.
Ask your AI about Axsome Therapeutics's goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude